Role of pramipexole in the management of Parkinsons disease

CNS Drugs

Volumn 24, Issue 10, 2010, Pages 829-841

  Antonini, Angelo ^a,b   Barone, Paolo ^c   Ceravolo, Roberto ^d   Fabbrini, Giovanni ^e   Tinazzi, Michele ^f   Abbruzzese, Giovanni ^g  

^a IRCCS SAN CAMILLO HOSPITAL   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c IDC Hermitage Capodimonte ^*  (Italy)

^d UNIVERSITY OF PISA   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY OF VERONA   (Italy)

^g UNIVERSITY OF GENOA   (Italy)

Author keywords

Parkinsons disease, treatment; Pramipexole, pharmacokinetics; Pramipexole, therapeutic use

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; CARBIDOPA PLUS LEVODOPA; ENTACAPONE; LEVODOPA; PERGOLIDE; PLACEBO; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE; SERTRALINE; TOLCAPONE;

ADD ON THERAPY; ADJUVANT THERAPY; AKINESIA; ANHEDONIA; CLINICAL TRIAL; DEPRESSION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; EDEMA; HALLUCINATION; HUMAN; IMPULSE CONTROL DISORDER; LUNG FIBROSIS; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; NAUSEA; NEUROPROTECTION; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; THERAPY EFFECT; TREMOR; VOMITING;

ANTIPARKINSON AGENTS; BENZOTHIAZOLES; DELAYED-ACTION PREPARATIONS; HUMANS; PARKINSON DISEASE;

EID: 77956672555     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11585090-000000000-00000     Document Type: Review

References (74)

1. Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 2009; 72 (21 Suppl. 4): S1-136
2. Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's disease: report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease. Eur J Neurol 2006; 13 (11): 1170-1185 (Pubitemid 44581464)
3. Piercey MF. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol 1998; 21 (3): 141-151
4. Maj J, Rogoi Z, Margas W, et al. The effect of repeated treatment with pramipexole on the central dopamine D3 system. J Neural Transm 2000; 107 (12): 1369-1379 (Pubitemid 32049933)
5. Wright CE, Sisson TL, Ichhpurani AK, et al. Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. J Clin Pharmacol 1997; 37 (6): 520-525
6. Hubble JP. Pre-clinical studies of pramipexole: clinical re-levance. Eur J Neurol 2000; 7 Suppl. 1: 15-20
7. Jenner P, Konen-Bergmann M, Schepers C, et al. Pharmaco-kinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies. Clin Ther 2009; 31 (11): 2698-2711
8. Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in pa-tients with early Parkinson's disease. Clin Neuropharmacol 1995; 18 (4): 338-347
9. Shannon KM, Bennett Jr JP, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease: the Pramipexole Study Group. Neurology 1997; 49 (3): 724-728
10. Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson disease: a randomized dose-ranging study. JAMA 1997; 278 (2): 125-130
11. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000; 284 (15): 1931-1938
12. Navan P, Findley LJ, Jeffs JA, et al. Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo onparkinsonian tremor. Mov Disord 2003; 18: 1324-1331
13. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004; 61(7): 1044-1053
14. Schrag A, Sampaio C, Counsell N, et al. Minimal clinically important change on the unified Parkinson's disease rating scale. Mov Disord 2006; 21 (8): 1200-1207
15. Noyes K, Dick AW, Holloway RG. Pramipexole versus levodopa in patients with early Parkinson's disease: effect on generic and disease-specific quality of life. Value Health 2006; 9 (1): 28-38
16. Parkinson Study Group CALM Cohort Investigators. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol 2009 May; 66 (5): 563-570
17. Chapuis S, Ouchchane L, Metz O, et al. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 2005; 20 (2): 224-230
18. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa: 056 Study Group. N Engl J Med 2000; 342 (20): 1484-1491
19. Rinne UK, Bracco F, Chouza C, et al. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of caber-goline and levodopa. The PKDS009 Collaborative Study Group. Neurology 1997; 48 (2): 363-368
20. Wermuth L. A double-blind, placebo-controlled, random-ized, multi-center study of pramipexole in advanced Parkinson's disease. Eur J Neurol 1998; 5 (3): 235-242
21. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997; 49: 162-168
22. Pinter MM, Pogarell O, Oertel WH. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatry 1999; 66 (4): 436-441
23. Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease: International Pramipexole-Bromocriptine Study Group. Neurology 1997; 49 (4): 1060-1065
24. Mizuno Y, Yanagisawa N, Kuno S, et al. Randomized, double-blind study of pramipexole with placebo and bro-mocriptine in advanced Parkinson's disease. Mov Disord 2003; 18 (10): 1149-1156
25. Weiner WJ, Factor SA, Jankovic J, et al. The long-term safety and efficacy of pramipexole in advanced Parkinson's disease. Parkinsonism Relat Disord 2001; 7 (2): 115-120
26. Moller JC, Oertel WH, Koster J, et al. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial. Mov Disord 2005; 20 (5): 602-610
27. Inzelberg R, Carasso RL, Schechtman E, et al.A comparison of dopamine agonists and catechol-O-methyltransferase inhibitors in Parkinson's disease. Clin Neuropharmacol 2000; 23 (5): 262-266
28. Pogarell O, Gasser T, van Hilten JJ, et al. Pramipexole in pa-tients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry 2002; 72 (6): 713-720
29. Poewe WH, Rascol O, Quinn N, et al. Efficacy of prami-pexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007; 6 (6): 513-520
30. Reichmann H, Odin P, Brecht HM, et al. Changing dopa-mine agonist treatment in Parkinson's disease: experiences with switching to pramipexole. J Neural Transm Suppl 2006; (71): 17-25
31. Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications: results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 1998; 55 Suppl. 1: 23-30
32. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006; 5 (8): 677-687
33. Olanow CW, Obeso JA, Stocchi F. Drug insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease. Nat Clin Pract Neurol 2006; 2 (7): 382-392
34. Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 2004; 19 (9): 997-1005
35. Albrecht S, Buerger E. Potential neuroprotection mechan-isms in PD: focus on dopamine agonist pramipexole. Curr Med Res Opin 2009 Dec; 25 (12): 2977-2987
36. Schapira AH. Neuroprotection in PD: a role for dopamine agonists? Neurology 2003; 61 (6 Suppl. 3): S34-42
37. Schapira AH, Olanow CW. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA 2004; 291 (3): 358-364
38. Carter AJ, Muller RE. Pramipexole, a dopamine D2 auto-receptor agonist, decreases the extracellular concentration of dopamine in vivo. Eur J Pharmacol 1991; 200 (1): 65-72
39. Le WD, Jankovic J, Xie W, et al. Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection.J Neural Transm 2000; 107 (10): 1165-1173
40. Carvey PM, Ling ZD. Pramipexole prevents levodopa-induced DA neurotoxicity in vitro implicating D3 receptors in neuroprotection [abstract]. Mov Disord 1996; 11 Suppl. 1: 179
41. Carvey PM, Pieri S, Ling ZD. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J Neural Transm 1997; 104 (2-3): 209-228
42. Parkinson Study Group. Dopamine transporter brain ima-ging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002; 287 (13): 1653-1661
43. Whone AL, Remy P, Davis MR, et al. The REAL-PET study: slower progression in early Parkinson's disease treated with ropinirole compared with levodopa [abstract]. Neurology 2002; 58 Suppl. 3: A82
44. Ahlskog JE. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology 2003; 60 (3): 381-389
45. 123I]b-CIT and SPECT imaging. Mov Disord 2007; 22 Suppl. 16: 143
46. Schapira A, Albrecht S, Barone P, et al. Immediate vs de-layed start pramipexole in early Parkinson's disease: the PROUD study [abstract]. Parkinsonism Relat Disord 2009; 15 Suppl. 2: S81
47. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009; 361 (13): 1268-1278
48. Miyasaki JM, Shannon K, Voon V, et al. Practice para-meter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66 (7): 996-1002
49. Hughes TA, Ross HF, Mindham RH, et al. Mortality in Parkinson's disease and its association with dementia and depression. Acta Neurol Scand 2004; 110 (2): 118-123
50. Barone P, Scarzella L, Marconi R, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J Neurol 2006; 253 (5): 601-607
51. Rektorova I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 2003; 10 (4): 399-406
52. Barone P, Poewe W, Tolosa E, et al. Efficacy of double-blind, placebo-controlled pramipexole against depression in Parkinson's disease [abstract]. Mov Disord 2009; 24 Suppl. 1: S347
53. Leentjens AF, Koester J, Fruh B, et al. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies. Clin Ther 2009; 31 (1): 89-98
54. Lemke MR, Brecht HM, Koester J, et al. Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease. J Neurol Sci 2006; 248 (1-2): 266-270
55. Antonini A, Tolosa E, Mizuno Y, et al. A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. Lancet Neurol 2009; 8 (10): 929-937
56. Tan EK, Ondo W. Clinical characteristics of pramipexole-induced peripheral edema. Arch Neurol 2000; 57 (5): 729-732
57. Kleiner-Fisman G, Fisman DN. Risk factors for the devel-opment of pedal edema in patients using pramipexole. Arch Neurol 2007; 64 (6): 820-824
58. Biglan KM, Holloway Jr RG, McDermott MP, et al. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. Neurology 2007; 69 (2): 187-195
59. Frucht S, Rogers JD, Greene PE, et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipex-ole and ropinirole. Neurology 1999; 52 (9): 1908-1910
60. Paus S, Brecht HM, Koster J, et al. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord 2003; 18 (6): 659-667
61. Hobson DE, Lang AE, Martin WR, et al. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA 2002; 287 (4): 455-463
62. Hauser RA, Gauger L, Anderson WM, et al. Pramipexole-induced somnolence and episodes of daytime sleep. Mov Disord 2000; 15 (4): 658-663
63. Antonini A, Cilia R. Behavioral adverse effects of dopa-minergic treatment in Parkinson's disease: incidence, neu-robiological basis, management and prevention. Drug Saf 2009; 32: 475-488
64. Voon V, Thomsen T, Miyasaki JM, et al. Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol 2007; 64 (2): 212-216
65. Weintraub D. Dopamine and impulse control disorders in Parkinson's disease. Ann Neurol 2008; 64 Suppl. 2: S93-100
66. Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross sectional study of 3090 patients. Arch Neurol 2010; 67: 589-595
67. Voon V, Hassan K, Zurowski M, et al. Prospective pre-valence of pathologic gambling and medication association in Parkinson disease. Neurology 2006; 66 (11): 1750-1752
68. Isaias IU, Siri C, Cilia R, et al. The relationship between impulsivity and impulse control disorders in Parkinson's disease. Mov Disord 2008; 23 (3): 411-415
69. Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 2007; 6 (9): 826-829
70. Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007; 356 (1): 39-46
71. Muller T, Fritze J. Fibrosis associated with dopamine ago-nist therapy in Parkinson's disease. Clin Neuropharmacol 2003; 26 (3): 109-111
72. Poewe W, Barone P, Hauser R, et al. Pramipexole extended-release is effective in early Parkinson's disease [abstract]. Move Disord 2009; 24 Suppl. 1: S273
73. Schapira AH, Barone P, Hauser R, et al. Efficacy and safety of pramipexole extended-release for advanced Parkinson's disease [abstract]. Mov Disord 2009; 24 Suppl. 1: S277
74. Rascol O, Barone P, Debieuvre C, et al. Easy switching from immediate-to extended-release pramipexole in early Parkinson's disease at the same daily dosage [abstract]. Mov Disord 2009; 24 Suppl. 1: S362